What is the diagnostic work‑up and treatment plan for an adolescent patient with suspected Bartter syndrome presenting with metabolic alkalosis, hypochloremia, and hypercalciuria?

Diagnostic Work-Up and Treatment for Adolescent Bartter Syndrome

In an adolescent with suspected Bartter syndrome presenting with metabolic alkalosis, hypochloremia, and hypercalciuria, immediately measure urinary fractional chloride excretion (should be >0.5%), obtain serum potassium and magnesium levels, assess urinary calcium-to-creatinine ratio, and proceed directly to genetic testing for confirmation while initiating potassium and sodium chloride supplementation. 1

Initial Diagnostic Algorithm

Step 1: Confirm Renal Salt Wasting

• Measure fractional chloride excretion: In Bartter syndrome, this is typically elevated (>0.5%), distinguishing renal from extrarenal salt losses 1
• Urinary sodium/chloride ratio: Helps confirm renal origin of electrolyte wasting
• Avoid obsolete diuretic challenge tests—these have been surpassed by genetic analysis and carry risk of severe volume depletion 1

Step 2: Distinguish Bartter from Gitelman Syndrome

The urinary calcium-to-creatinine ratio is the critical discriminator 2:

• Molar ratio >0.20: Bartter syndrome (hypercalciuria or normocalciuria)
• Molar ratio ≤0.20 with serum magnesium <0.75 mmol/L: Gitelman syndrome (hypocalciuria with hypomagnesemia)

This distinction is clinically essential because adolescent presentation typically suggests Type 3 Bartter syndrome (onset 0-5 years, variable calcium excretion) or Gitelman syndrome (usually diagnosed at school age with tetanic episodes) 1, 2

Step 3: Complete Biochemical Profile

Obtain simultaneously:

• Serum electrolytes: Hypokalemia and hypochloremia are universal; check for hypomagnesemia (mild in Bartter, severe in Gitelman)
• Plasma renin and aldosterone: Expect hyperreninemic hyperaldosteronism despite normotension 1
• Renal ultrasound: Assess for nephrocalcinosis (common in Types 1,2, and variable in Type 3) 1
• Plasma Cl/Na ratio: Normal in Types 1-2, decreased in Types 3-4 1

Step 4: Exclude Mimics Before Genetic Testing

Critical differential diagnoses in adolescents 1, 3:

• Diuretic or laxative abuse: Most common mimic—check urine toxicology
• Cystic fibrosis: Pseudo-Bartter from sweat salt loss—obtain sweat chloride test
• Congenital chloride diarrhea: Presents with watery diarrhea and similar electrolyte pattern
• Primary hyperaldosteronism: Excluded by clinical context (hypertension absent in Bartter)

Genetic Confirmation

Proceed directly to comprehensive genetic testing targeting the five Bartter syndrome genes 1:

• Type 1: SLC12A1 (NKCC2)
• Type 2: KCNJ1 (ROMK)
• Type 3: CLCNKB (ClC-Kb) — most likely in adolescent presentation
• Type 4a: BSND (Barttin) — associated with sensorineural deafness
• Type 4b: CLCNKA + CLCNKB (both ClC-Ka and ClC-Kb)

Important technical note: Large gene rearrangements are particularly frequent in CLCNKB and require confirmation by multiplex ligation-dependent probe amplification (MLPA) if detected by next-generation sequencing 1

Offer genetic counseling to the family, including cascade screening of relatives 1

Treatment Plan

Immediate Management

1. Sodium chloride supplementation: Essential cornerstone therapy 4

   • High-dose oral NaCl (varies by severity, typically 3-6 mEq/kg/day in divided doses)
   • Adolescents require lifelong supplementation

2. Potassium replacement: 4, 5

   • Oral potassium chloride (not other salts—chloride is critical)
   • Expect high requirements (often 2-4 mEq/kg/day)
   • Monitor closely as refractory hypokalemia is common

3. Potassium-sparing diuretics: 5

   • Spironolactone (aldosterone antagonist): Start 1-2 mg/kg/day divided BID
   • Helps reduce potassium losses but may worsen hypovolemia
   • Particularly useful when hypokalemia remains refractory despite supplementation

Prostaglandin Inhibition (Type-Specific)

Indomethacin or celecoxib for Types 1,2, and 4 (antenatal/severe forms) 4, 6:

• Reduces prostaglandin E2-mediated polyuria and electrolyte wasting
• Less effective in Type 3 (adolescent-onset), which typically has milder phenotype
• Celecoxib preferred in long-term use due to better GI tolerability (2.5 mg/kg BID) 6
• Monitor for renal function deterioration

Magnesium Supplementation

• Not typically required in Bartter syndrome (only mild hypomagnesemia in Type 1)
• If serum magnesium <0.75 mmol/L with hypocalciuria, reconsider Gitelman diagnosis 2, 4

Long-Term Monitoring and Complications

Essential Follow-Up Parameters

• Quarterly monitoring: Serum electrolytes, renal function, growth parameters
• Biannual renal ultrasound: Track nephrocalcinosis progression (risk factor for CKD in Types 1,2,4) 1
• Annual assessments: Hearing evaluation (if Type 4a with BSND mutation), bone density (chronic alkalosis risk)

Critical Pitfalls to Avoid

1. Intercurrent illness management: Even minor infections cause rapid electrolyte deterioration—increase supplementation immediately and monitor closely 6
2. Growth monitoring: Chronic salt wasting impairs growth; endocrinology consultation if growth velocity declines 6
3. Cardiovascular surveillance: Chronic hypokalemia increases arrhythmia and cardiovascular event risk 5
4. Avoid NSAIDs in Type 3: Limited benefit and potential nephrotoxicity in milder phenotypes

Prognosis Considerations

• Type 3 (most likely in adolescents): Generally favorable with treatment adherence; lower risk of CKD compared to antenatal types 1
• Nephrocalcinosis presence: Increases CKD risk—requires aggressive hydration and electrolyte management
• Treatment adherence: Most patients achieve normal life with strict adherence to supplementation regimen 7

The hypercalciuria in this patient strongly suggests Type 1,2, or possibly Type 3 Bartter syndrome rather than Gitelman syndrome, making genetic confirmation essential for prognostication and family counseling 1, 2.